23andMe, Pfizer release Lupus Research Study jointly 23andMe, Inc., the leading personal genetics firm, announced the launch of the Lupus Research Study in collaboration with Pfizer Inc today. The ongoing companies aim to enroll 5,000 people with systemic lupus erythematosus, even more known as lupus commonly, into the study to greatly help better understand the genetics of lupus precautions . The effort is usually in collaboration with the Lupus Research Institute also, and in concert with Lupus Consciousness Month in May. Approximately 1.5 million people in the U.S. Suffer from lupus, an autoimmune disease in which the disease fighting capability can attack the standard, healthy tissues of the body almost anywhere.
Not only are these fresh genetic findings significant, but we’ve also shown that the info gathered by 23andMe support discovery of fresh associations along with replication of previously known associations. This research is a rigorous proof of principle and clearly demonstrates that web-based phenotyping works for a disease of real public health significance. 23andMe carried out its research utilizing a scholarly study cohort of 3,426 PD instances assembled in collaboration with The Parkinson’s Institute and Clinical Center and The Michael J. Fox Foundation. Sufferers had been recruited through a targeted email campaign by The Parkinson’s Institute and The Michael J. Fox Foundation, along with other Parkinson’s patient organizations and clinics.